Sign in
Taking people in South KoreaNo phase

Tests an AI-assisted heart stent procedure in people with coronary artery disease

Tests an AI-assisted artery-opening procedure in adults with narrowed heart arteries.

Key facts

Who runs it
CHA University
Where
Daegu, Gwangju, Gwangmyeong, Jeonju, Seongnam-si, and Ulsan, South KoreaSee the 6 sites
Trial code
Registry title
Medipixel XA-Assisted PCI in Coronary Artery Disease
Status
Recruiting
People taking part
830 people, planned
Started
15 May 2025
Expected to end
May 2028
Type of study
Interventional
Treatments tested
  • Medipixel XA-Assisted Percutaneous Coronary Intervention
Record updated
21 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with coronary artery disease who have a new blockage in a heart artery that can be treated with a drug-eluting stent.

Age
19 years and older
Sex
All sexes can join.
Disease stage
Silent ischemia, stable or unstable angina, or myocardial infarction, with a de novo coronary lesion that can be treated with a drug-eluting stent (DES) and can be analyzed by MPXA.

Main reasons for not taking part

  • Other illness with a life expectancy under 12 months
  • Cannot tolerate antithrombotic therapy
  • Significant anemia, thrombocytopenia, or leucopenia
  • History of major bleeding (intracranial, gastrointestinal, and so on)
  • Chronic total occlusion lesion, left main lesion, or severe calcification needing rotational atherectomy

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Silent ischemia, stable or unstable angina, or myocardial infarction
  • De novo coronary lesion eligible for DES implantation
  • Lesions analyzable by MPXA

Who cannot take part

  • Intolerant of antithrombotic therapy
  • History of major hemorrhage (intracranial, gastrointestinal, and so on)
  • Comorbidity with a life expectancy <12 months
  • Significant anemia, thrombocytopenia, or leucopenia
  • Chronic total occlusion lesion
  • Left main lesion
  • Severe calcification needing rotational atherectomy
  • Lesions not analyzable by MPXA

Where in South Korea

  • Keimyung University - Dongsan Medical CenterDaegu, South KoreaContact: Yoon-Joo BaeTaking people
  • Chonnam National University HospitalGwangju, South KoreaContact: Min-Jee KimTaking people
  • Chung-Ang University Gwangmyeong HospitalGwangmyeong, South KoreaContact: Ji-Sook SeoTaking people
  • Presbyterian Medical CenterJeonju, South KoreaContact: Jong Pil ParkTaking people
  • CHA Bundang Medical CenterSeongnam-si, South KoreaContact: Hwa-In KimTaking people
  • Ulsan University HospitalUlsan, South KoreaContact: Min-Jung ParkTaking people

About the trial

What the trial wants to find out

This prospective, multicenter, single-arm, interventional study evaluates the effectiveness and safety of Medipixel XA-Assisted Percutaneous Coronary Intervention (MPXA-PCI) in patients with coronary artery disease (CAD). The study aims to assess procedural success rates and clinical outcomes associated with the novel MPXA-assisted PCI strategy in a real-world clinical setting.

Read full original descriptionShow less

A total of 830 patients with de novo coronary lesions eligible for drug-eluting stent (DES) implantation will be enrolled. All participants will undergo MPXA-assisted lesion assessment to optimize balloon and stent selection. The primary outcome is target vessel failure (TVF) at 12 months, defined as a composite of cardiac death, target vessel-related myocardial infarction, and clinically driven target vessel revascularization. Secondary outcomes include procedural success, angiographic results, and periprocedural complications.

This study will provide evidence regarding the clinical applicability and safety of artificial intelligence-assisted quantitative coronary analysis (AI-QCA) technology for optimizing PCI procedures.

The group in the trial

  • Medipixel XA-Assisted PCI GroupTreatment being tested

    Treatment: Medipixel XA-Assisted Percutaneous Coronary Intervention

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Medipixel XA-Assisted Percutaneous Coronary Intervention in Coronary Artery Disease: A Prospective Multicenter Study
Plain-language title
Tests an AI-assisted heart stent procedure in people with coronary artery diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
21 October 2026